Bayesian decision theory can be used not only to establish the optimal sample size and its allocation in a single clinical study but also to identify an optimal portfolio of research combining different types of study design. Within a single study, the highest societal payoff to proposed research is achieved when its sample sizes and allocation between available treatment options are chosen to maximize the expected net benefit of sampling (ENBS). Where a number of different types of study informing different parameters in the decision problem could be conducted, the simultaneous estimation of ENBS across all dimensions of the design space is required to identify the optimal sample sizes and allocations within such a research portfolio. This is illustrated through a simple example of a decision model of zanamivir for the treatment of influenza. The possible study designs include: 1) a single trial of all the parameters, 2) a clinical trial providing evidence only on clinical endpoints, 3) an epidemiological study of natural history of disease, and 4) a survey of quality of life. The possible combinations, samples sizes, and allocation between trial arms are evaluated over a range of cost-effectiveness thresholds. The computational challenges are addressed by implementing optimization algorithms to search the ENBS surface more efficiently over such large dimensions.
Bayesian decision theory can be used not only to establish the optimal sample size and its allocation in a single clinical study but also to identify an optimal portfolio of research combining different types of study design. Within a single study, the highest societal payoff to proposed research is achieved when its sample sizes and allocation between available treatment options are chosen to maximize the expected net benefit of sampling (ENBS). Where a number of different types of study informing different parameters in the decision problem could be conducted, the simultaneous estimation of ENBS across all dimensions of the design space is required to identify the optimal sample sizes and allocations within such a research portfolio. This is illustrated through a simple example of a decision model of zanamivir for the treatment of influenza. The possible study designs include: 1) a single trial of all the parameters, 2) a clinical trial providing evidence only on clinical endpoints, 3) an epidemiological study of natural history of disease, and 4) a survey of quality of life. The possible combinations, samples sizes, and allocation between trial arms are evaluated over a range of cost-effectiveness thresholds. The computational challenges are addressed by implementing optimization algorithms to search the ENBS surface more efficiently over such large dimensions. Key words: Bayesian decision theory; expected value of information; research design; cost-effectiveness analysis. (Med Decis Making 2009;29:643-660) H ealth care systems typically face 2 conceptually separate, albeit concurrent, questions: first, should a health care technology be adopted (reimbursed) in light of current evidence about resource use and health outcomes? Second, is additional research required to support the use of the technology, and if so, how much and what type of research would be most useful? Both questions are at the heart of much of the international debate about the appropriate regulation and reimbursement of health care technologies. In general, decisions to adopt (reimburse) or reject a technology can be made on the basis of existing information or conditional on providing additional evidence to inform this decision in the future. In the United States, the Food and Drug Administration (FDA) requires claims for a technology to be ''sufficiently substantiated,'' based on some assessment of the benefits and costs of acquiring more information to support the claim. 1 In England and Wales, the National Institute for Health and Clinical Excellence (NICE), which issues guidance to the National Health Service (NHS) on the use of technologies, also issues guidance on the need for further research. 2 It has made adoption conditional on the production of further evidence and, in some circumstances, has made recommendations that a technology can only be used in research. 3 Addressing the question of whether and what type of research is needed becomes more challenging when the full range of different types of study and different designs that could be conducted are considered. In most situations, a variety of different types of study, informing different (groups of) parameters or endpoints, is usually possible. For instance, although randomized controlled trials (RCTs) are useful to investigate those clinical endpoints vulnerable to selection bias, other (not necessarily experimental) studies may be called upon to collect information about the natural history of a disease of interest or some measure of quality of life associated with particular clinical events. To start to address these research decisions, we need a measure of the social value of the information generated by research.
Methodological Background
The Bayesian approach to value of information has a firm foundation in statistical decision theory. [4] [5] [6] [7] [8] [9] It provides a coherent framework to establish the social value of additional information, which has been successfully applied in other areas of research [10] [11] [12] and more recently proposed in the evaluation of health care technologies. [13] [14] [15] [16] [17] In particular, an increasing number of applications in this area have incorporated an analysis of the value of perfect information. [18] [19] [20] [21] [22] [23] However, the demonstration and application of value of sample information analysis are more limited, 18, [24] [25] [26] [27] and to date, no attempt has been made to explore all the dimensions of design space available using these methods.
A Bayesian decision-theoretic approach can establish the population expected value of perfect information (EVPI) surrounding a decision to adopt or reject a technology. Population EVPI places an upper bound on the social value of additional evidence and provides a necessary condition for deciding to conduct further research (i.e., if the population EVPI is greater than the expected costs of further studies). The expected value of perfect parameter information (EVPPI) associated with specific (groups of) parameters relevant to the decision problem can be established in a similar fashion. This can be used to focus further research on those parameters where additional evidence will be most valuable and can indicate the types of studies that may be most useful. However, fully informing the research decision requires a sufficient condition to be established. The expected net benefit of sampling (ENBS) for a particular type of study and sample size is the difference between the expected value of sample information (EVSI) and the costs of sampling. Therefore, the ENBS is a measure of the social value of a particular proposed research design. It provides a sufficient condition for deciding to conduct more research (i.e., if ENBS is greater than 0). It also provides the means to choose between different types of study and different designs. The research decision can then be characterized as choosing the type of study or studies and design(s) that maximizes the ENBS.
Design Space
In its simplest form, research design can be formulated as a sample size determination problem 18, [24] [25] [26] [27] [28] [29] : under this perspective, the design problem reduces to identifying the optimal size for each of the studies that could be conducted. The optimal sample size for a single study will be the sample size that generates the greatest ENBS. For studies that include a number of treatment arms (e.g., an RCT comparing a new technology to one or more alternatives), not only the optimal total number of patients to enroll needs to be sought but also their optimal allocation to each treatment arm. Equal between-arm allocation is often adopted based on a simplifying assumption of equal variance for each arm. However, this assumption is seldom justified and, even if it were, the resource and opportunity cost of allocation to different arms is very unlikely to be the same. Therefore, when only considering a single RCT, both optimal sample size and its allocation need to be established. 30 It is seldom the case that a single RCT is the only research possibility. If more than one type of study can be conducted, then optimal sample size and its allocation can be established for each study independently. If these are mutually exclusive alternatives, then the research decision is simply to choose the optimally designed single study that offers the highest ENBS. However, in many common circumstances, different types of study are not mutually exclusive and can be conducted concurrently. The social value of a combination of studies (a portfolio) is not the sum of the ENBS of each but must be estimated simultaneously. The portfolio optimization problem becomes one of finding the allocation of patients between and within studies that provides the maximum ENBS. The optimal portfolio size and allocation will generally be different from that implied by a simple combination of independent designs. The research decision problem becomes one of a choice between a number of alternative single studies and an optimally designed portfolio. This choice can be based on the ENBS offered by each.
The purpose of this article is to demonstrate the principles and methods for the thorough assessment of all these dimensions of the design space. Its aim is to show that Bayesian decision theory can provide a coherent and useful analytical framework to estimate the social value of research, establish optimal research designs, and inform the research decision. The article proceeds by introducing an illustrative example of a simple decision model of zanamivir for the treatment of influenza, reporting estimates of cost and effect based on the then-current information. Then, necessary and sufficient conditions for conducting further research reported before optimal research designs are considered in more detail. A single RCT with equal allocation is considered first, and then unequal allocation is introduced. Subsequently, other types of study are introduced, first optimized independently and then simultaneously as a portfolio. The research decision is then reconsidered once the analyses of all these dimensions of design space have been explored. In doing so, we adopt an optimization algorithm that eases the computational challenges arising from using Bayesian decision theory to optimize over such large dimensions of design space.
AN ILLUSTRATIVE EXAMPLE
The principles of adopting a Bayesian decisiontheoretic approach to research decisions are illustrated using a simple numerical example of the use of zanamivir in the treatment of influenza. The example is used to demonstrate how research design space might be more fully explored and was selected to be sufficiently simple to ease exposition and to allow the evaluation of the optimization methods developed below. NICE conducted an appraisal of zanamivir in 2000 and issued guidance, 31 which imposed a number of restrictions and conditions on its use. In particular, treatment should only be offered when influenza is circulating in the community and for at-risk adults who present within 36 hours of the onset of influenza-like illness. At-risk adults were defined as those older than age 65 or those with chronic respiratory disease, significant cardiovascular disease, and immunocompromised and those with diabetes mellitus.
The NICE appraisal of zanamivir was based on an independent assessment report, 32 to which the reader is referred for full details of the evidence available at that time, and the cost-effectiveness analysis. In summary, the assessment report identified 9 RCTs, but the evidence for at-risk adults is based on subgroup analysis of 8 of the all-adult trials and 1 trial that only recruited adults with chronic respiratory disease. The trials reported time to alleviation of symptoms for the influenza-positive population as well as the number of complications requiring antibiotics. The assessment report included fixed effect meta-analysis for both these endpoints. None of the trials included effect on hospitalization or economic and quality-of-life data.
A simple decision tree model was constructed to compare zanamivir with standard care. The proportion of influenza-positive patients presenting with influenza-like illness (pip) was based on evidence from a sponsored submission. 33 The probability of complications requiring antibiotics and the probability of hospitalization with standard care (pcs and phs) was based on observational data. 34 The reduction in symptom days (rsd) was based on the results of the fixed effect meta-analysis. The reduction in complications for those receiving zanamivir was based on the log-odds ratio from the same meta-analysis (LORc), and a similar effect on hospitalization (LORh) was assumed. The improvement in quality of life due to reduced symptom time (utl) was based on an assumed impact on all dimensions of the EQ5D. Resource use was based on published unit costs, hospital length of stay, and number of general practitioner (GP) visits. [32] [33] [34] [35] A probabilistic reanalysis of this model was conducted, based only on the information that was publicly available in the assessment report at the time the guidance was issued. The uncertainty surrounding the decision to adopt zanamivir for this patient group was characterized by assigning prior distributions to each of the key parameters and is detailed in Table 1 . For simplicity and ease of exposition, these parameters were assumed to be independent, which in the absence of evidence of correlation is consistent with the original analysis in Burls and others. 32 Unit prices and resource use were assumed to be known. Monte Carlo (MC) simulation was conducted to obtain the joint distributions of costs and effects and net benefit 36 for a range of cost-effectiveness thresholds (l). Zanamivir is more costly but more effective than standard care, with an expected incremental costeffectiveness ratio of 51,700. The cost-effectiveness acceptability curve is illustrated in Figure 1a 37, 38 and indicates that when λ = 60,000 per quality-adjusted life year (QALY) gained, zanamivir is expected to be cost-effective, but this decision is uncertain with an error probability of 0.534. It should also be noted that the probability that zanamivir is cost-effective at l = incremental cost-effectiveness ratio (ICER) is less then 0.5, indicating that the prior distribution of the expected incremental net benefit offered by zanamivir is positively skewed. 37 
IS ADDITIONAL RESEARCH REQUIRED?
In the absence of sunk costs or other irreversibilities, 26, 39, 40 the technology that is expected to be cost-effective should be selected based on current information. However, a second decision also needs to be made: is additional research required to support the use of the technology, and if so, how much and what type of research would be most useful?
Necessary Condition for Further Research
The EVPI surrounding the decision to adopt or reject a technology places an upper bound on the social value of additional evidence and a necessary condition for deciding to conduct further research (i.e., further research is potentially worthwhile only if the population EVPI is greater than the expected costs of further studies).
A decision model with unknown parameters W yields (typically by MC simulation) a distribution for the net benefits NB t (W) of each treatment option t = 1, . . . , T for a homogeneous patient population. After characterizing the uncertainty around model parameters W by assigning prior probability distributions (see Table 1 ), the EVPI for an individual patient is defined as
Given current information, the adoption decision only can be made before the uncertainty about model parameters W resolves for all evaluated treatment options-that is, choose the alternative that maximizes the expected net benefit E W [NB t (W)]. In principle, perfect information about W would allow maximization of the actual net benefit NB t (W) for any particular value of W, hence yielding max t NB t (W); however, because the true values are unknown, such maximum values need to be averaged over the joint distribution of W, which in turn leads to E W [max t NB t (W)]. Thus, the EVPI is the difference in social payoff when making decisions with perfect rather than current information. 18 Although EVPI indicates the maximum social value of information about the decision problem, it does not indicate which type of evidence (which 18 Having divided model parameters W = (j, c) into nuisance (c) and relevant (j) parameters of interest,
quantifies the maximum social value of acquiring information about j alone. With perfect knowledge about parameters of interest j, the decision maker is able to identify the technology yielding highest expected net benefit (with respect to the residual uncertainty about c) max t E c j j [NB t (j, c)]. However, as in the case of EVPI, the true value of j is unknown so that an additional expectation E j max t f E c j j [NB t (j, c)]} over the prior distribution of j needs to be evaluated. It should be noted that EVPI does not additively decompose into its individual EVPPI components due to the presence of interactions occurring within the model structure. 7, 12 Expression (1) or (2) provides the EVPI or EVPPI for each time this decision is made (i.e., for an individual patient or individual patient episode). These values need to be expressed for the current and future population that could benefit from further research. If Q h patients (or episodes) enter the decision problem at year h = 1, . . . , H over the time horizon for the decision problem H, the population EVPI, or PEVPI at discount rate r, 
is obtained. Both Q h and H are in principle also subject to uncertainty. The choice of H can be shown to be a proxy for a complex and uncertain process of future changes influencing the value of different types of information on future periods that can be acquired today. 23 In this example, we assume H = 7 years, Q h = 136,000, and r = 6%, which reflects the time until the initial decision was expected to be reviewed (when lower prices and new competitors were expected to be available)-estimates of the presenting eligible patient population in an average year 32 and the discount rate used in the original analysis. Estimates of population EVPI and EVPPI over a range of cost-effectiveness thresholds are illustrated in Figure 1b . At cost-effectiveness thresholds greater that 30,000 the population EVPI is likely to exceed the costs of further investigation, and further research may be worthwhile. The EVPPI associated with reduction in symptom days on zanamivir is relatively high, but a more precise estimate would require experimental design to avoid selection bias. This suggests that a further randomized trial may be worthwhile. However, there are other parameters associated with significant EVPPI (most notably the quality of life associated with influenza symptoms and the probability that a patient presenting with influenza-like symptoms does in fact have influenza), which may not require experimental design and could be informed by an observational study or a survey of quality of life.
Sufficient Condition for Further Research
The estimates of population EVPI and EVPPI only provide an upper bound on the social value of research. However, fully informing the research decision requires a sufficient condition to be established based on the expected benefits and costs of particular proposed research designs. Sample information would allow an update of (imperfect) prior knowledge of model parameters into a posterior distribution for W conditional on the collected data. This is formally done by combining each prior distribution with the likelihood for a given sample data x by means of Bayes theorem. 41 Thus, proposed research, generating prospective data x to be collected from a sample of n patients, will inform parameters W. The expected social value of evidence generated by the design n is then expressed by the expected value of sample information 18 :
which measures the additional value of the adoption decision when based on sample, rather than current information. Analogously to (2) , the information about W conveyed in x would allow the decision maker to establish which treatment yields highest expected net benefit E W x j [NB t (W)]. Due to the sampling variability surrounding x, a further expectation over its predictive distribution is needed (first term at the RHS of (4)). At a particular cost-effectiveness threshold, the EVSI for all parameters converges to the EVPI as sample size increases and provides an upper bound to EVSI. As with EVPI, the EVSI needs to be expressed for the population of current and future patients who will benefit from this information. The population EVSI for proposed research with sample sizes n is given by
The estimation of EVSI(n) poses greater challenges than EVPI because both inner and outer expectations within the first term of (4) can be computationally burdensome, especially with non-multi-linear decision models. 18 , * In this simple example, both logodds ratios of complications and hospitalization are modeled via a normal approximation to binomial likelihoods (see Table 1 ), and second-order Taylor series expansions were also invoked to ensure multilinearity and are recommended in computations involving nonlinear parameter transformations in otherwise linear net benefit functions. 18 The PEVSI(n) needs to be compared to the costs of sampling C(n), which includes both resource and opportunity costs incurred by the n t patients allocated to each treatment option t (with P t n t = n): where t * = arg : max : t E W [NB t (W)] indicates the treatment option yielding the highest expected net benefit given current information. The first term of (6) includes the fixed (c f ) and reporting (c t , applied to all involved sample sizes and summed over competing treatment options) resource costs, the second term includes expected benefits from the research that will be forgone by those patients enrolled in the study (the population that can benefit from the results of the research is ''used up''), and the third term includes the expected net benefit forgone by those patients allocated to the treatment(s) that are not a priori costeffective. The social value of proposed research is the difference between expected benefits (PEVSI(n) and costs, C(n)) or the expected net benefit of sampling:
This provides a sufficient condition for deciding to conduct more research-that is, only if ENBS(n) is greater than 0 is further research justified. It also provides the means to choose between different types of study and different designs (sample size and its allocation). The research decision can now be characterized as choosing the type of study or studies and design(s) that maximizes the ENBS.
RESEARCH DESIGN SPACE
Ideally, the research design n * yielding the highest ENBS over a range of sample sizes should be sought and implemented. In principle, this defines a relatively straightforward integer programming problem, where the objective function ENBS( · ) is to be maximized over the examined design space D of study sizes n. Complications, however, arise in practice due to the nature of the objective function: in most situations, exact ENBS evaluation is not possible due to the nested expectation and maximization required in the definition (4) of PEVSI. The problem of ENBS( · ) not being generally available in closed form is usually circumvented by replacing (7) with a suitable approximation, ensuring that the maximum it produces would consistently estimate n * . A number of approximation-based solutions dealing with difficulties in PEVSI calculations recently appeared in the statistical literature. 24, 42, 43 The most established and straightforward method 44 that is also adopted throughout this article relies on the empirical MC estimatorÊNBS(n). This is obtained from taking sample averages over both the predictive distribution of the data x (for the outer expectation in (4)) and the posterior distribution of the model inputs W conditional on data x (for the inner expectation).
Designing a Single Study
A simple research design that would inform the zanamivir v. standard care decision problem consists of an RCT allocating an equal number of entrants to its arms (a fixed sample design). This trial, if conducted and planned to have sufficient follow-up to inform all outcomes relevant to subsequent cost-effectiveness analysis (CEA), would provide observations on all the parameters that could be updated simultaneously using the likelihoods reported in Table 1 and exploiting convenient conjugacy to form posteriors. In this case, the ENBS maximizing design n * indicates how many patients should be enrolled in the trial for it to provide the highest social value. This initial simplicity of the design space (D = N) allowed full enumeration of a sufficient range of sample sizes to identify the optimal sample size and the maximum ENBS at very high MC resolutions (50 6 iterations). Figure 2 and the first 2 rows of Table 2 summarize the results of fully exploring this limited design space when fixed costs c f are excluded for simplicity, as they do not influence optimal sample size (or its allocation), and reporting costs c Std and c Zan for each arm are assumed equal at 600 per patient. Figure 2a illustrates PEVSI(n), C(n), and ENBS(n) for a range of sample sizes when l = 50,000. As expected, PEVSI(n) increases with n but at a declining rate, approaching PEVPI in the limit. Therefore, the ENBS reaches a ''nonsharp'' maximum where the ENBS curve is relatively flat (i.e., sample sizes slightly greater or less than optimal have little impact on ENBS). Figure 2b illustrates ENBS curves at 3 cost-effectiveness thresholds over the same range of sample sizes. The ENBS is highest when l = 50,000, reflecting the fact that the decision is most uncertain (see Figure 1a ), and information is more valuable when l = 50,000 rather than l = 60,000 or l = 40,000 (see Figure 1b) . Again, the ENBS curve is relatively flat at its maximum. The optimal sample size also changes with the cost-effectiveness threshold. This relationship is explored more fully in Figure 2c , which plots the optimal sample size for a range of costeffectiveness thresholds. At l < 30,000, the optimal sample size is 0, and no further research is needed. When l > 30,000, the optimal sample size increases with l reaching a maximum of 999 at l = 61,000 and declines thereafter because the increased opportunity costs incurred by enrolled patients start to outweigh the marginally diminishing gains generated from additional sample information. Figure 2b , c shows that both the value of conducting research and its optimal design (in this case, only sample size) depend critically on economic considerations represented by the costeffectiveness threshold.
Optimization Algorithms
The limited design space D = N considered above makes an exhaustive search for n * using estimates of ENBS at very high MC resolutions feasible. However, such an exhaustive search is unlikely to be possible when the other dimensions of the design space described are considered because the computational burden increases geometrically with the dimensions that need to be explored-for example, simply considering optimal allocation of each possible sample between 2 arms of a trial doubles the dimensions of D and increases the design space from D = N to D = N 2 . One way of mitigating this ''curse of dimensionality'' is to replace the previous exhaustive search with a more efficient search for the maximum ENBS and the associated optimal sample size. A number of more efficient searches or optimization algorithms are available that, when started at a randomly chosen point, will evaluate ENBS at candidate sample sizes iterating to the sample size that provides the maximum ENBS. The improved adaptive Nelder-Mead simplex method 45 was adopted for its robustness and parsimony in general multivariate optimization settings. This optimization algorithm searches for the global maximum on the ENBS surface through the evaluation of repeated iterations. If the surface is smooth with a single maximum, then a single optimization routine started at any point would be sufficient to identify the maximum ENBS and optimal sample size-that is, the estimated optimum will be independent of the initial value (if convergence occurs before the maximum number of iterations is reached). † However, althoughÊNBS(n) from MC simulation is a consistent estimator of (7), the estimated surface ENBS( · ) is rough, and its roughness depends on the MC resolution used in its estimation. This rough surface does not preserve the convergence properties underpinning most optimization algorithms, and a single optimization routine will not necessarily locate n * . However, the sample average approximation 46 indicates that the estimated optimal designn = arg max n ∈ DÊ NBS(n) converges to the optimal design n * = arg max n ∈ D ENBS(n) at an exponential rate with the MC resolution. If the surface is rough, the initial value for the optimization routine may continue to influence the estimated optimum even after a number of iterations. This suggests that a number (L) of repeated optimization routines are required, each starting at random across a wide range of initial sample sizes. ‡ This multiple optimization provides a sample of estimated optimal sample sizesn 1 , . . . ,n L and associatedÊNBS( · ) values. This sample of estimates provides an interval for n * and ENBS(n * ), with the average optimal sample size ( n = P ln L) and average maximum ENBS (ENBS = P lÊ NBS l =L) providing central estimates. By selecting the number of repeated optimizations and the MC resolution used to estimate each candidate ENBS, a range representing the precision of optimal design estimates can be established within feasible computing time. A narrower range can be achieved with higher MC resolutions but at the cost of additional computation time. Of course, a sufficient number of repeated optimizations need to be conducted to ensure that the range of estimated optimal values includes the optimum (this will tend to be greater for lower MC resolutions as the surface will be rougher).
An indication of the performance of this approach to optimization in terms of computing time, the intervals, and central estimates for n * and ENBS(n * ) is possible by comparison with the results of an exhaustive search at very high MC resolutions (taken to represent ''true'' values of n * and ENBS(n * )). Optimization was applied to the D = N RCT design 518,600-536,700 2,076,800-2,103,500 1,608,300-1,626,000 ‡ The range of initial values was chosen to be sufficiently wide to comfortably include the maximum based on an initial small number of pilot optimizations. Uniform maximin Latin hypercube sampling was used to ensure a wide and representative range of possible values where sampled. A comparison of outcomes for L = 100, L = 500, and L = 1000 indicated that the range of estimated optimum values was very stable and central estimates were similar. † The optimization routine was set to be conservative with a maximum of 10 4 iterations and able to detect very small differences in ENBS (convergence tolerance). The number of iterations required to reach convergence in the analysis below was always at least an order of magnitude lower than the maximum. described above, and the results are illustrated in Figure 3a when using L = 1000, each starting at random over the range 1, . . . , 1500 f gand with a MC resolution of 10 5 for each of the candidate estimates of ENBS. § An informal comparison of Figures 2b and 3a shows the optimization performs well, locating optimal sample size and the maximum ENBS. These results are reported in more detail in Table 2 and confirm that the interval that includes 95% of estimated optima included n * and ENBS(n * ), and the sample mean of these estimates was close to these ''true'' values at each of the 3 cost-effectiveness thresholds. The interval for n * clearly tends to be wider than the relatively narrow ranges for ENBS(n * ). This is due to the relative flatness of the ENBS surface around its maximum that, when combined with MC noise, reduces the precision of inferences about n * but enables accurate estimation of the relatively stable ENBS(n * ). As might be expected, the sampling variability of the estimates appears to be greater at cost-effectiveness thresholds where decision uncertainty is greater (those closer to the ICER). Overall, optimization appears to provide reliable estimates of n * and ENBS(n * ). It also gives an indication of the precision of estimated optima and substantially reduces computation time with an optimization to an exhaustive search ratio of 1/8 user computing time.
In the simple D = N research design considered above, the ENBS can be expected to reach a single global maximum. * * However, for higher dimensional design problems, there may not necessarily be a single maximum on the ENBS surface, so a single optimization routine may locate a local rather than a global maximum, even on a smooth surface. Therefore, using a number of repeated optimization routines, each starting at random points across the design space, ensures that at least some estimates will locate the global rather than a local maximum. If the distribution of the estimates of maximum ENBS is bi-or multimodal, it will indicate the presence of a local maximum. In these circumstances, the central estimate and range should not be based on all the estimated values but on those associated with the mode yielding on average highest ENBS estimates. For all the dimensions of design space explored below, the distribution of the estimates of maximum ENBS was found to be unimodal, indicating that in this example, at least the ENBS surface had a single maximum for all the designs explored.
Optimal Sample Allocation
So far, the exploration of research design space has been restricted to a single RCT allocating an equal number of entrants to its arms and informing all parameters. The problem is simply to identify the sample size that maximizes ENBS (i.e., a single dimension of design). However, evaluation of the alternative designs available requires consideration of both the total number of patients to enroll and how they should be allocated between each of the alternative interventions available. The benefits of allocating patients to different arms of a trial will tend to differ because the prior variance of the net benefit of each intervention is unlikely to be the same (a sample will tend to provide more valuable information when prior variance is greater). Also, the costs of allocating patients to different arms are unlikely to be the same because even if the reporting costs are the same (as in this case), the opportunity costs (net benefit forgone) will differ between the arms of the trial (when l 6 ¼ ICER). For these reasons, the assumption of equal allocation is unlikely to be justified. 30 In this example, the problem is to establish the total sample size and its allocation between the 2 arms that provide the maximum ENBS, n * = (n * Std , n * Zan ). The design space increases from 1 (D = N) to 2 dimensions (D = N 2 ), and the computational burden makes the type of exhaustive search at high MC resolutions illustrated in Figure 2 infeasible. The optimization algorithm described above was implemented, and the results for 3 values of l are illustrated in Figure 3b and reported in Table 2 . Informal inspection of Figure 3b suggests that in this example, the optimal allocation does not differ markedly from equal allocation (the rising diagonal)the joint density of the estimated n * Std and n * Zan combinations is diffuse and covers equal allocation. This might be expected as the variance of the net benefit of the 2 arms is similar, and the only difference in sampling costs is the expected net benefit forgone (third term in (6)). However, when l > ICER, the optimal allocation does suggest that more of the sample should be allocated to standard care-that is, when the prior decision favors zanamivir, it is additional information about standard care rather than zanamivir that is more likely to revise this decision. This is due to the positive skewness in the incremental net benefit of zanamivir compared to standard care, where those parameters requiring some of the sample to be allocated to zanamivir contribute most to this skewness. † † These additional benefits of allocation to standard care outweigh the * * The PEVSI increases with sample size ultimately at a declining rate, and although the costs of sampling also increase at a declining rate, they do so more slowly than the PEVSI because 2 of the 3 elements of (6) increase at a constant rate, and the third (EVSI forgone) necessarily decreases at the same rate as the PEVSI. † † Those parameters that require some of the sample to be allocated to zanamivir (i.e., LORc, LORh, and rsd) contribute most to the positive skewness. Clearly, the distribution of predicted posterior values must also be positively skewed, but its skewness will depend on which parameters are being updated and with ''how much'' sample information. Therefore, when proportionately more patients are allocated to zanamivir, the distribution of predicted posterior values tends to be more positively skewed and less so when more patients are allocated to the standard care arm. When l > ICER, the mean incremental net benefit is positive, so it is only predicted posterior values on the left of this distribution that could revise the prior decision, which is in favor of zanamivir, and generate value to research. If this distribution is less positively skewed (more sample allocated to standard care), then such values are more likely, and the EVSI will be greater. Conversely, when l < ICER, the mean incremental net benefit is negative, and only predicted posterior values on the right of this distribution could revise the prior decision, which is in favor of standard care. If this distribution is more positively skewed (greater allocation to zanamivir), then such values are more likely, and the EVSI becomes greater.
additional opportunity costs of sampling (the expected net benefit forgone). The general point is that the benefits of allocating the sample to different arms of a trial do not just depend on the differences in the variance of net benefit but also on the effect of sample information on its shape. Optimal allocation allows designs to be adopted that either provide more benefit for a particular total sample size and/or reduce the costs of sampling. Therefore, the maximum ENBS must be greater with optimal allocation, but the total sample size may not necessarily be higher as more efficient use is made of a smaller sample when allocated efficiently. The results reported in Table 2 confirm this. The estimated maximum ENBS is higher at each of the 3 cost-effectiveness thresholds, although not markedly so, reflecting the similarity between optimal and equal allocations. The optimal total sample size is higher with optimal allocation when l = 50,000 but lower at 40,000 and 60,000. The intervals for the total optimal sample size are wider than with equal allocation, reflecting the greater complexity of the design space. The intervals for the maximum ENBS, however, are narrower, indicating that the ENBS surface with optimal allocation is ''flatter,'' and therefore estimates are more stable at the maximum. This is because there are multiple combinations of (n Std , n Zan ) producing ENBS values that are similar and close to the maximum.
DESIGNING A PORTFOLIO OF STUDIES
A single RCT that simultaneously informs all the parameters is not the only type of research that could be conducted. Only some of the parameters (reduction in symptom days and the log-odds ratios for complication and hospitalization) require experimental design to avoid selection bias. Other parameters associated with significant EVPPI (see Figure 1b ) may not require experimental design and could be informed by other designs. For example, a survey of quality of life could be undertaken to estimate the quality of life associated with influenza symptoms. An observational epidemiological study could be designed to estimate the probability that a patient presenting with influenza-like symptoms does in fact have influenza, as well as the baseline probabilities of complication and hospitalization. If more than one type of study can be conducted, then optimal sample size and its allocation can be established for each type of study independently. If these are mutually exclusive alternatives, then the research decision is simply to choose the optimally designed single study that offers the highest ENBS. However, if they are not mutually exclusive but can be conducted together, the ENBS of the combination (portfolio) is not the sum of the ENBS of each but must be estimated simultaneously.
Individual Study Designs
Three alternative types of study can be considered: a simple RCT that only provides information about the clinical endpoints (i.e., rsd, LORc, and LORh) that are vulnerable to selection bias; an epidemiological study updating pip, pcs, and phs; and a survey of quality of life providing estimates of utl. The maximum ENBS and optimal sample size can be established for each study independently of the others. Therefore, if these alternatives are regarded as mutually exclusive, then 1 search over 2 dimensions of design space (optimal sample size and allocation) for the clinical trial, n Trl = n Std + n Zan , and 2 separate 1-dimensional searches for optimal sample size for the epidemiological study n Epi and survey of quality of life n Utl are required.
The optimal design of each of these independent mutually exclusive studies is illustrated in Figure 4 when l = 50,000, and details are provided in Table  3 at 3 cost-effectiveness thresholds. Of these 3 studies, the clinical trial provides the highest ENBS with an optimal sample size much larger than the RCT updating all parameters in Figure 2 . This is due to the lower reporting costs of this simpler design (300 rather than 600) and the fact that the clinical endpoint of reduction in symptom days is associated with the highest value of information. ‡ ‡, § § It should be noted that the interval for the optimal sample size of this design is greater than previously, reflecting ‡ ‡ When the marginal sampling costs are lower, the optimal sample size will always be higher and the ENBS surface flatter at its maximum, all other things being equal. This trial includes rsd, which is associated with the highest value of information but has a less diffuse prior, so the PEVSI increases more slowly with sample size. It also excludes those parameters with more diffuse prior distributions where PEVSI increases rapidly with n. The combined effect leads to a higher optimal sample size on a ''flatter'' ENBS surface. § § Only the estimated optimal total sample sizes rather than the optimal allocation between standard care and zanamivir can be represented in 2 dimensions in Figure 4 . Due to computational burden, an exhaustive search at very high MC resolution is only possible and illustrated for the single-dimensional designs of an epidemiological study and a survey of quality of life. the relative ''flatness'' of the ENBS surface. * * * The survey of quality of life generates the next highest ENBS but at the lowest optimal sample size. This is for 3 reasons: it is associated with high PEVPPI (see Figure 1b ); it has a diffuse prior, which means that relatively small amounts of sample information are valuable (PEVSI increases rapidly with n Utl ); and the reporting costs are assumed to be relatively high (500). Consequently, the ENBS curve has a more pronounced maximum, and the 95% interval for the estimates of optimal sample size is relatively narrow. The epidemiological study generates a lower ENBS but at a higher sample size. This should be expected given the lower PEVPPI associated with these parameters (see Figure 1b) , relatively low reporting costs (200), and less diffuse prior distributions.
If all the 4 studies considered and reported in Tables 2 and 3 are regarded as mutually exclusive, then the research decision is simply to choose the optimally designed single study that offers the highest ENBS. In these circumstances, it would be the RCT that simultaneously informed all the parameters (see Table 2 ). This optimally designed study provides an estimated maximum ENBS that is greater than the ENBS of any one of the other 3 studies considered individually (see Table 3 ) at each cost-effectiveness threshold. However, the 3 studies reported in Table 3 are not necessarily mutually exclusive and could be conducted simultaneously. The ENBS for this combination of independently designed studies is not the sum of the individual ENBS but the ENBS for the combination of the optimal sample sizes previously identified for each study. The ENBS for the combination of independently designed studies is reported in the last rows of Table 3 . This is greater than the ENBS for the single RCT informing all parameters when l = 50,000 or l = 60,000. However, at a lower costeffectiveness threshold of l = 40,000, the single RCT would be better than the combination of the 3 independently designed studies.
Optimal Portfolio Design
Although relatively straightforward to implement, the strategy of designing each study independently before combining them to construct a portfolio of research will generally fail to identify the optimal combination that maximizes ENBS. Identifying individual research designs independently is suboptimal because it neglects the relationships between studies designed to investigate different but related aspects of the same decision problem-that is, it assumes that the contribution provided by each study (the parameters they investigate) to the value of information is additive. Therefore, the optimal design of a portfolio of research can be regarded as finding the total sample size that, when allocated optimally between different studies and/or arms of studies, will maximize ENBS. In this example, it requires simultaneously searching for n * = (n * Std , n * Zan , n * Epi , n * Utl ). The computational scale of this problem and the need for optimization should be apparent-the dimensions of the design space are now 4 (D = N 4 ). Despite the scale of this problem, the optimization procedures outlined above can be used to provide central estimates of total sample size, its allocation, maximum ENBS, and the associated 95% intervals. Computational burden can be made feasible by the selection of a sufficient number of optimization routines at a manageable MC resolution. Therefore, the feasibility of exploring the design space is not really a question of whether it is feasible but more a question of what precision is affordable.
The results of optimization over these 4 dimensions of design space are illustrated in Figure 5 and reported in more detail in Table 4 . Figure 5a designed studies will not necessarily be the same as an optimal portfolio, which simultaneously allocates the sample between different studies and the arms of studies. There are similarities, however: for example, the relative size of total sample allocated to the clinical trial, epidemiological study, and the survey of quality of life is similar. Also, within the clinical trial, optimal allocation to the 2 arms is similar to previous results (see Table 2 ) where a greater proportion is allocated to standard care when l < ICER but more to zanamivir when l > ICER. † † † However, these differences in allocation are smaller with independent design rather then simultaneous optimization across these studies. One noticeable difference, at l = 40,000, is that optimal sample size for the epidemiological study is 0, indicating it should be excluded from the portfolio of research when designed independently of the others. However, when designed simultaneously, the sample size is positive and should be included in a portfolio of research. Simultaneous allocation within and between studies allows optimal portfolios to be identified that either provide more benefit for a particular total sample size and/or reduce the costs of sampling. Therefore, the maximum ENBS must be greater with optimal design, but the total sample size may not necessarily be higher as more efficient use is made of a smaller sample when allocated optimally. In this case, the overall total sample size of the optimal portfolio is lower than the combination of individually designed studies at l = 50,000 or l = 60,000 (i.e., it makes more efficient use of a smaller sample) but is greater when l = 40,000. The ENBS for the optimal portfolio reported in Table 4 confirms that the ENBS for an optimally designed portfolio always exceeds the ENBS for the combination of individually designed studies reported in Table 3 at each of the cost-effectiveness thresholds.
DISCUSSION
A Bayesian decision-theoretic approach to both adoption and research decisions means that a rational and consistent approach to both is possible. The decision to adopt a technology can be based on expected net benefits (while explicitly taking account of any sunk costs and other irreversibilities) rather than traditional rules of inference. Similarly, research design issues cannot be resolved using simple universal rules of precedent either (e.g., the traditional power calculation is based on established benchmarks of power and statistical significance and can be seen as essentially arbitrary). Efficient research design is an empirical and partly economic question determined by the characteristics of the decision problem, the prior information available, and the monetary valuation of health outcome that will be applied once the research is completed and an adoption decision must be made. In other words, the efficient design of research cannot be separated from the objectives and constraints on service provision. To date, most applications of Bayesian decision theory and value of information analysis have been restricted to establishing the expected value of perfect information, so they can only provide a necessary condition for conducting further research and cannot address the question of efficient research design. The demonstration and application of an analysis of the expected value of sample information have been more limited and restricted to considering the value and optimal sample size of a single study to inform a decision to adopt or reject a technology. The analysis reported above demonstrates that Bayesian decision theory and optimization can be combined to more fully inform the research decision by exploring more dimensions of research design space. The research decision is not simply a binary question of whether to conduct further research or not, nor is it restricted to the more complex question of the optimal size of a single study. The research decision requires an examination of much wider dimensions of design space, including how patients should be allocated between the arms of a single study as well as the range of possible combinations of different types of studies that could be conducted to inform particular uncertain parameters. In this particular example, even when considering a single study with fixed sample design, the optimal allocation of patients between the arms of the proposed trial is important even when the direct costs of allocation between different arms are the same. As well as an efficiently designed single trial informing all parameters (with optimal sample size and allocation), the research decision space also includes 1) conducting a simpler (and cheaper) clinical trial, providing evidence only on clinical endpoints; 2) an epidemiological study of natural history of disease; and 3) a survey of quality of life. The research decision requires not only consideration of each of these independent alternatives but also their possible combinations. The example demonstrates that where a number of different types of study informing different parameters in the decision problem could be conducted, the simultaneous estimation of ENBS across all dimensions of the design space is required to identify the optimal sample sizes and allocations within such a research portfolio.
The illustrative numerical example was selected to be sufficiently simple to ease exposition and to allow evaluation of the optimization methods through full enumeration at a very high MC resolution. The use of multiple optimization routines provided informative and reliable 95% intervals as well as central estimates of optimal sample size, allocation, and maximum societal payoff to research. However, the computational challenges of exploring these wider dimensions of design space are considerable and would be even greater in more complex applications where there is a nonlinear relationship between the parameters and net benefit, the assumption of independence cannot be sustained, or conjugacy cannot be exploited. However, the use of more efficient algorithms to search the ENBS surface for its maximum rather than exhaustively search over such large dimensions makes the task more feasible and substantially reduces computation time. Indeed, by selecting a sufficient number of optimization routines at a manageable MC resolution, it is not really a question of whether it is feasible to explore these additional dimensions of design space but rather a question of what precision is affordable and useful. Even relatively imprecise intervals may be useful to decision makers if they can indicate whether further research may be required (the ENBS exceeds the fixed costs of research), the types and combination of studies that are likely to be most valuable, and at what scale they will be worth conducting. Of course, there may be aspects of value not captured in net benefit or opportunity costs of research not included in ENBS that are important to decision makers. Also, evidence about some types of parameters (e.g., the natural history of the disease or quality of life associated with particular health states) may be valuable in more than one context and may continue to be valuable beyond the life span of the technology. Nevertheless, this type of explicit analysis may provide a useful and accountable starting point for deliberations about research prioritization and commissioning.
Other dimensions of possible design space have not been explored in this example. Most important, the question of sequential design has not been considered. Sequential issues arise in 2 respects. First, it has been assumed that the proposed trials are a fixed sample rather than sequential design, where the results from earlier trial entrants are available and able to inform the allocation of subsequent patients. A substantial body of literature exists that examines the optimal allocation of entrants in sequential clinical trials, [47] [48] [49] [50] but traditional approaches to this problem, which favor patient allocation into the most effective arm in light of its interim results, tend to neglect the dynamics of the marginal benefits and costs of sample information and hence fail to address the issue of socially efficient design. Second, in constructing the portfolio, it was assumed that all studies would be conducted concurrently, so the results from one could not inform the design of another. It is possible to consider the order in which different studies could be conducted. For example, it might be better to conduct a survey of quality of life before designing and conducting a clinical trial. However, it should be apparent that the dimensions of this design space are considerable, requiring estimates of social payoff for every possible subsequent sequence and possible design conditional on every predicted posterior for each initial sample size. This becomes even more burdensome when there are sequential issues within and between the studies under consideration.
There are ways to reduce the scale of this type of problem using dynamic programming. However, using Bayesian decision theory and value of information analysis to fully explore the design space that arises from these types of sequential problems is an area for future investigation.
